Metformin Reframed as a Gut-Targeted Mitochondrial Therapy for Glycaemic Control : Nat Metab | May 2026

Introduction

Metformin remains the cornerstone first-line therapy for type 2 diabetes mellitus, yet its dominant therapeutic mechanism has remained controversial for decades. While traditional models emphasized hepatic gluconeogenesis suppression, emerging evidence increasingly points toward the intestine as a central therapeutic site of action.

Problem Statement

The concentrations required for direct mitochondrial complex I inhibition are generally achieved in the intestine rather than the liver during standard metformin dosing, raising uncertainty regarding the true biologic target responsible for metformin-induced glucose lowering, enhanced intestinal glucose uptake and postprandial glycaemic control.

Summary

This landmark study demonstrates that metformin exerts its principal glucose-lowering effects through selective inhibition of mitochondrial complex I within intestinal epithelial cells. Using human metabolomic datasets and genetically engineered mice expressing metformin-resistant yeast NDI1 specifically in intestinal epithelium, the investigators established that intestinal complex I inhibition is essential for multiple hallmark clinical effects of metformin. Mechanistically, metformin transformed the intestine into a high-capacity glucose disposal organ by increasing intestinal glucose uptake, accelerating glycolysis and promoting conversion of glucose into lactate and lactoyl-phenylalanine. Metformin also suppressed citrulline synthesis, a mitochondrial-dependent metabolic process unique to small intestinal epithelium, providing a clinically measurable biomarker of intestinal mitochondrial inhibition. Importantly, resistance to intestinal complex I inhibition markedly attenuated metformin-induced improvements in glucose tolerance, postprandial glycaemia and pyruvate tolerance in both lean and obese mice. The study further demonstrated that metformin’s efficacy depends on repeated acute bolus exposure rather than cumulative chronic metabolic remodeling, supporting the clinical importance of mealtime dosing. Beyond metformin, phenformin and berberine were shown to share the same intestine-specific mitochondrial complex I–dependent mechanism, suggesting a broader therapeutic paradigm centered on gut-restricted mitochondrial modulation. These findings substantially redefine metformin pharmacology by shifting the primary mechanistic focus from hepatic gluconeogenesis toward intestinal mitochondrial bioenergetics and glucose disposal. The work also opens new avenues for development of gut-selective mitochondrial therapeutics aimed at optimizing glycaemic control while minimizing systemic toxicity.